Legend Biotech Quarterly Balance Sheets Chart
Quarterly
|
Annual
Legend Biotech Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2022-12-31 | 2022-06-30 | 2021-12-31 | 2021-06-30 | 2020-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| non-current assets | |||||||||
| property, plant and equipment | 105,278 | 108,725 | 109,503 | 110,978 | 105,168 | 106,181,000 | 145,724 | 135,216,000 | 113,091 |
| advance payments for property, plant and equipment | 563 | 451 | 419 | 1,061 | 914 | 191,000 | 2,168 | 2,197,000 | 224 |
| right-of-use assets | 80,179 | 80,502 | 74,811 | 78,497 | 55,590 | 39,423,000 | 7,186 | 7,312,000 | 8,009 |
| time deposits | 4,387 | 4,362 | 4,268 | 4,209 | 4,470,000 | 4,705 | 174,644,000 | 50,000 | |
| intangible assets | 3,152 | 4,061 | 4,009 | 2,465 | 3,409 | 4,624,000 | 4,684 | 4,681,000 | 2,852 |
| collaboration prepaid leases | 166,344 | 151,216 | 135,997 | 119,173 | 65,276 | ||||
| other non-current assets | 1,412 | 1,493 | 1,531 | 1,414 | 1,487 | 31,911,000 | 5,148 | 4,885,000 | 3,973 |
| total non-current assets | 361,315 | 350,810 | 330,538 | 317,797 | 231,844 | 186,800,000 | 169,615 | 154,291,000 | 128,149 |
| current assets | |||||||||
| collaboration inventories | 22,146 | 19,433 | 18,014 | 15,196 | 10,354 | 8,158,000 | |||
| trade receivables | 3,307 | 100,041 | 20 | 15,064 | 90 | 461,000 | 50,410 | 15,000,000 | 74,978 |
| prepayments, other receivables and other assets | 85,603 | 69,251 | 66,569 | 66,573 | 61,755 | 42,143,000 | 12,754 | 11,170,000 | 10,007 |
| financial assets at fair value through profit or loss | 150,449 | 663 | 185,792 | 185,756 | 185,603 | ||||
| pledged deposits | 359 | 357 | 356 | 1,246 | 1,270 | 1,402,000 | 1,444 | ||
| cash and cash equivalents | 897,571 | 1,277,713 | 963,470 | 1,233,213 | 786,031 | 379,776,000 | 688,938 | 488,215,000 | 455,689 |
| total current assets | 1,413,792 | 1,497,799 | 1,508,796 | 1,612,862 | 1,099,119 | 835,945,000 | 948,752 | 720,834,000 | 592,858 |
| total assets | 1,775,107 | 1,848,609 | 1,839,334 | 1,930,659 | 1,330,963 | 1,022,745,000 | 1,118,367 | 875,125,000 | 721,007 |
| current liabilities | |||||||||
| trade payables | 39,485 | 20,160 | 17,173 | 21,544 | 32,893 | ||||
| other payables and accruals | 136,012 | 132,802 | 144,651 | 165,519 | 184,109 | 116,842,000 | 123,464 | 109,183,000 | 99,168 |
| government grants | 538 | 68 | 630 | 435 | 451 | 315,000 | 304 | 300,000 | 283 |
| lease liabilities | 3,116 | 3,175 | 2,915 | 3,558 | 3,563 | 2,122,000 | 911 | 1,178,000 | 1,464 |
| tax payable | 7,273 | 7,203 | 9,853 | 10,326 | 9,772 | 9,339,000 | |||
| contract liabilities | 63,251 | 53,010 | 60,644 | 56,139,000 | 55,014 | ||||
| total current liabilities | 249,675 | 216,418 | 175,222 | 201,382 | 297,788 | 259,756,000 | 280,266 | 261,101,000 | 161,167 |
| non-current liabilities | |||||||||
| collaboration interest-bearing advanced funding | 286,396 | 281,328 | 275,906 | 270,614 | 260,932 | 189,218,000 | |||
| lease liabilities long term | 45,174 | 44,169 | 41,687 | 44,444 | 20,039 | ||||
| other non-current liabilities | 30 | 56 | 119 | 152 | 233 | 314,000 | 396 | 554,000 | 554 |
| total non-current liabilities | 361,373 | 380,820 | 324,476 | 322,246 | 288,863 | 200,357,000 | 366,895 | 274,105,000 | 279,585 |
| total liabilities | 611,048 | 597,238 | 499,698 | 523,628 | 586,651 | 460,113,000 | 647,161 | 535,206,000 | 440,752 |
| equity | |||||||||
| share capital | 36 | 36 | 36 | 36 | 33 | 31,000 | 31 | 29,000 | 27 |
| reserves | 1,164,023 | 1,251,335 | 1,339,600 | 1,406,995 | 744,279 | 562,601,000 | 471,175 | ||
| total ordinary shareholders’ equity | 1,164,059 | 1,251,371 | 1,339,636 | 1,407,031 | 744,312 | 562,632,000 | 471,206 | 339,919,000 | |
| total equity | 1,164,059 | 1,251,371 | 1,339,636 | 1,407,031 | 744,312 | 562,632,000 | 471,206 | 339,919,000 | |
| total liabilities and equity | 1,775,107 | 1,848,609 | 1,839,334 | 1,930,659 | 1,330,963 | 1,022,745,000 | 1,118,367 | 875,125,000 | 721,007 |
| warrant liability | 67,000 | 118,900,000 | 87,900 | 83,300,000 | |||||
| financial assets measured at amortized cost | 29,937 | ||||||||
| collaboration lease receivables | 671,000 | ||||||||
| trade and notes payables | 12,238,000 | 7,043 | 11,001,000 | 5,238 | |||||
| inventories | 1,749 | 1,700,000 | 1,800 | ||||||
| interest-bearing loans and borrowings | 120,462 | 17,310,000 | |||||||
| financial investment measured at amortized cost | 29,849,000 | ||||||||
| pledged short-term deposits | 256,000 | 384 | |||||||
| reserve | 339,890,000 | ||||||||
| deferred tax assets | |||||||||
| reserves/ | 280,228 | ||||||||
| total ordinary shareholders’ equity/ | 280,255 | ||||||||
| total equity/ | 280,255 |
We provide you with 20 years of balance sheets for Legend Biotech stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Legend Biotech. Explore the full financial landscape of Legend Biotech stock with our expertly curated balance sheets.
The information provided in this report about Legend Biotech stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.